Send me real-time posts from this site at my email

Why Sorrento Therapeutics Stock Is Jumping Today

What happened

Shares of small-cap biotech Sorrento Therapeutics (NASDAQ: SRNE) were up by a noteworthy 13.3% on heavy trading volume as of 11:24 a.m. ET Tuesday. What's particularly interesting about this double-digit percentage move is that the company hasn't announced any significant material events in about a month.

So what's going on? Sorrento's shares were some of the hardest hit in its industry during the first half of 2022. The biotech stock shed an eye-catching 56% of its value amid that downturn. In that context, Tuesday's uptick appears to be the result of bargain hunters positioning for a possible rally among small-cap biotechs in the second half of the year.

So what

Why are some investors growing more optimistic that the worst might be over for small-cap biotech stocks? One possibility is that their valuations have gotten so low that big pharma players and blue-chip biotechs might start to scoop up companies with promising pipelines at discounted prices. Sorrento, with its broad pipeline of immunotherapies, cancer drugs, and COVID-related product candidates, might be an attractive takeover target.

Now what

Is Sorrento's stock a buy on this sudden trend reversal? Fundamentally speaking, it does appear to be undervalued -- even after Tuesday morning's uptick. Keeping with this theme, the biotech's late-stage lung cancer drug candidate, abivertinib, arguably supports its current valuation. And when you add in the net present value of its other pipeline candidates, Sorrento's stock starts to look like an absolute steal at current levels.

10 stocks we like better than Sorrento Therapeutics
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now... and Sorrento Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of June 2, 2022

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.


Popular posts

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue